Immunology and Therapeutic Antibodies

This note covers the ACE2 receptor mechanism and a further monoclonal antibody application. Hybridoma technology, the general mechanism behind how a monoclonal antibody is manufactured, and its use in pregnancy tests and in trastuzumab against breast cancer, are covered in Microbes, Immunity and Modern Biotechnology.

ACE2: a receptor the body needs, that a virus learned to exploit

ACE2 (Angiotensin-Converting Enzyme 2) is a genuine, functional human cell-surface receptor with its own normal physiological job, regulating blood pressure as part of the renin-angiotensin system, entirely unrelated to any virus. Coronaviruses, including SARS-CoV-2, exploit this receptor as their entry point into human cells: a spike protein on the virus's surface binds to ACE2, and that binding is the first physical step that lets the virus fuse with and enter the cell.

This is the fact worth holding precisely for an exam: ACE2 is not something the virus brought with it or built for itself, it is a pre-existing human receptor the virus has simply learned to bind. Which cells in the body carry more ACE2 receptors on their surface is also directly relevant to which tissues a coronavirus infection affects most severely, since a receptor's presence is what makes a cell a viable entry target in the first place, and its absence is a large part of why other cells are relatively protected.

A further monoclonal antibody application: Nipah virus

Beyond diagnostic (pregnancy test kits) and cancer-targeting (trastuzumab) uses, monoclonal antibodies have also been trialled and used experimentally in outbreak response, including against the Nipah virus, a serious and periodically re-emerging zoonotic threat in parts of India. The underlying principle is the same one covered elsewhere: a monoclonal antibody is a laboratory-engineered protein designed to bind with high specificity to one particular target antigen, here a Nipah virus surface protein, mimicking and boosting the immune system's own ability to neutralise the pathogen. What differs is the setting: rather than a routine diagnostic kit or an elective cancer therapy, this is monoclonal antibody technology deployed as an emergency treatment during an active disease outbreak, where a specific, fast-acting intervention matters more than a broad-spectrum one.

Quick revision points

• ACE2 is a normal human cell-surface receptor (part of blood-pressure regulation), not a viral component. Coronaviruses, including SARS-CoV-2, bind to ACE2 as their entry point into human cells; a cell's ACE2 density affects how vulnerable that tissue is to infection.
• Monoclonal antibodies have been used experimentally against the Nipah virus in outbreak response, the same underlying antigen-binding principle as diagnostic and cancer-therapy uses, applied instead as an emergency intervention during a live outbreak.
• Hybridoma technology (how a monoclonal antibody is actually manufactured) and its pregnancy-test and trastuzumab/HER2 applications are covered in Microbes, Immunity and Modern Biotechnology.